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A B S T R A C T
Knowledge of cardiovascular risk factors is increasing. At the same time, risk estimation becomes more and more dif-
ficult. The need for a more comprehensive, but more individually based approach is evident. To achieve this aim, we pro-
pose a systems biology approach in cardiovascular risk assessment. This means that a large amount of health data, de-
scribing many aspects of the health-status of patients, is collected and computed and the results are compared with
existing knowledge. Finally, a clinical model is created, which can be the first step in ongoing research protocol, aimed at
assessing cardiovascular risk. By using this approach, all potentially relevant risk factors can be identified on a small
sample. Moreover, risk groups can be more specifically defined, based on the »natural« clustering of data, according to
their predictive load. We tested this possibility on an example of hyperhomocysteinemia which is a well-known complex
cardiovascular risk factor.
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Introduction
Prediction of cardiovascular diseases (CVD) is based
on the risk factor paradigm. Classical risk factors, includ-
ing: hypertension, cigarette smoking, dyslipidemia, obe-
sity and diabetes, have long been established1,2. In addi-
tion to these classical risk factors, evidence suggests the
existence of new factors, including: low-grade inflamma-
tion, chronic latent infections, e.g. with Cytomegalovirus
or Helicobacter pylori, hypercoagulability, hyperhomocy-
steinemia (elevated serum concentrations of amino acid
homocysteine), or increased oxidative stress3,4. It has
also been established that complex psychological and so-
cioeconomic factors strongly influence risk and prognosis
in CVD5,6.
The addition of these »new« factors can be used for
stratifying the risk of CVD more accurately. In this re-
gard, there are indications that most coronary events oc-
cur in persons with risk factor values in the middle of the
distribution, rather than at extremes7–9. This may be a
consequence of the fact that risk factors are heteroge-
neously distributed in the population. Hence, the same
risk factors do not show the same effect in different pop-
ulation groups3,9. The problem is, however, that large,
multi-centric and long-term studies are needed to prove
the validity of these »new« factors in cardiovascular risk
assessment.
As knowledge of the risk factors and mechanisms in-
volved in the development of CVD increases, the prepa-
ration of risk estimation tables and scores becomes more
and more difficult10. Two contradictory, but also comple-
mentary, demands are evident: the need for a more com-
prehensive and at the same time a more individually
based approach11. Thus, for example, early strategies
used single risk factors to assess the relative risk of se-
vere events: myocardial infarction, sudden cardiac death
and stroke. On the contrary, the currently recommended
method is a multiple point score system based on the use
of several major risk factors for determination of a 10-
-year absolute risk of severe events1,10–12. However, even
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this new system is deficient in classifying complex clini-
cal conditions, such as diabetes mellitus, or the metabolic
syndrome, or in verifying the subclinical form of athero-
sclerotic disease, or positive family history for CVD11–13.
In general, a more definite answer is needed on the
question of how many parameters (and which ones)
should be measured to adequately cover subjects at in-
creased risk for severe cardiovascular events. The chal-
lenge will also be to determine if more than one specific
subgroup of patients at increased risk for CVD can be
identified in the population.
The aim of this study is to show that collecting health
data systematically, describing many aspects of the health-
-status of patients, and use of computer-based tech-
niques for data analysis could enable identification of all
potentially relevant risk factors for CVD even on a small
sample, avoiding the need for multiple, large-scale stud-
ies. We tested this possibility on a model of hyperhomocy-
steinemia.
Hyperhomocysteinemia as a cardiovascular and
common ageing disease risk factor
Hyperhomocysteinemia has recently been recognised
as an important cardiovascular risk factor14. Moreover,
based on intensive basic and clinical research, mild hy-
perhomocysteinemia (>12 mM) has been accepted as a
common risk factor for the development of many age-re-
lated phenotypes, including: atherosclerosis, thrombosis,
depression, neurodegenerative diseases and cancer15. In
addition, it is assumed to be due to many underlying
causes, all connected with increasing age, such as: B-vi-
tamin deficiency, chronic gastritis, chronic renal impair-
ment, thyroid gland dysfunction and other chronic condi-
tions, as well as medical treatments16,17.
Thus, hyperhomocysteinemia, alone, represents a com-
plex trait18.
Materials and Methods
Study population
The study was conducted in a general practice, situ-
ated in an urban area (the city of Osijek, approximately
90 000 inhabitants), in the eastern part of Croatia, char-
acterised by a high prevalence of cardiovascular and
other chronic disorders, higher than the average for
Croatia6,19. Approximately 1600 patients, registered on
the list of one family doctor, were used as the population
sample. Two thirds of the patients were aged 50 years or
more.
A total number of 93 patients, 35 male and 58 female,
50–89 years old (median 69), out of 150 individuals re-
quiring the influenza vaccine in the season 2003/2004,
gave their consent and were enrolled in the study. They
were all patients having chronic medical conditions. The
study protocol was approved by the local ethics commit-
tee.
Systems biology approach
We used a systems biology approach21. In contrast to
the classical, reductionist methodology approach, this
approach is not strongly hypothesis-driven, but is based
on the use of research protocol. This means that the basic
information is gathered from publications. The model is
created on the basis of these pieces of information and
tested by experiment, or computer-based simulation (a
model-building approach). The results are then used to
make corrections to the model22,23.
Contrary to the reductionist methodology approach,
where only a few recognisable variables can be evaluated
– a systems biology approach is an analysis of how all
components in a biological system interact to determine
a particular phenotype. This requires integration of a
large amount of heterogenous data. In this way, much
hidden information can be revealed22,23.
Dataset
Based on a systems methodology approach, we deter-
mined the health status of the subjects according to sev-
eral aspects, systematically. For this purpose, a total
number of 52 parameters were collected, including: age
and sex, frequently used drugs, diagnoses of the main
groups of chronic diseases, anthropometric measureme-
nts, cognitive impairment test and a set of haematologi-
cal and biochemical tests24.
Blood tests were chosen on the basis of two criteria: 1)
to determine the main age-related pathogenetic changes
and 2) to be available in a real health care system setting.
Based on these criteria, we performed blood tests to de-
termine: inflammation, nutritional status, metabolic sta-
tus, latent infections (Helicobacter pylori and Cytomega-
lovirus), chronic renal impairment and neuroendocrine
status.
Our intention was not to use all possible factors con-
nected with the ageing process, but to assess the princi-
ples and possibilities of a systems biology approach in
solving different medical problems.
Testing the method on the model of
hyperhomocysteinemia
Since many factors in our dataset had previously been
identified in published papers as being associated with
hyperhomocysteinemia, we used a model of hyperhomo-
cysteinemia to check the accuracy of the applied method
to extract relevant information from the data.
For that purpose, we made minor corrections to the
primarily performed dataset, by changing some of the
data. The final number of the data was 43 (Table 1 and
2).
We then defined the aims of the study.
¿ Since hyperhomocysteinemia has been identified as
a cardiovascular risk factor having multiple connec-
tions with a wide range of age-related disorders, the
role of this model was to indicate that a wider back-
ground of common ageing disorders should be con-
sidered when assessing the total cardiovascular risk.
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¿ Another aim was to show that the same dataset,
with only minimal corrections, can be used for solv-
ing several research tasks. That assumption was
based on the observation that common ageing dis-
eases result from complex interactions between
multiple genetic variants and environmental fac-
tors and that these factors are shared between re-
lated disorders25,26.
¿ The main aim of this study was to create a clinical
model which represents all elements of the net-
worked reaction producing hyperhomocysteinemia.
¿ Association studies linking hyperhomocysteinemia
and diabetes mellitus have achieved conflicting re-
sults.This question is expected to be solved by the
creation of a clinical model of hyperhomocysteine-
mia27.
Blood sampling
Blood samples for haematological and biochemical
analyses were collected from each subject. Haematologi-
cal analyses were carried out on fresh blood samples,
while sera for biochemical analyses were separated by
centrifugation and stored at –40°C until assayed. All
blood tests were performed in the Central Biochemical
Laboratory of Osijek University Hospital Center, using
standard techniques (Table 2).
For the main purpose of this study, homocysteine con-
centrations were determined. Its median estimated value
was 11.8 mol/L. This was very close to the cut-off value of
12 mol/L, found to be associated with increased risk for
cardiovascular disease and all-cause mortality14.
Data Mining methodology
Data Mining is an advanced computer-based tech-
nique, operating on the principles of searching for recog-
nisable patterns and structures in the data28,29.
In this study, algorithms of the ILLM (Inductive
Learning by Logic Minimization) system, developed in
the Laboratory for information Systems, Department of
Electronics, »Rudjer Bo{kovi}« Institute, Zagreb, were
applied30.
The main characteristics of Inductive Learning meth-
ods are that parameters describing patients (called at-
tributes) can acquire any of three types of values, includ-
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TABLE 1
QUALITATIVE DATA USED TO DESCRIBE THE HEALTH STATUS OF SUBJECTS
Parameter Positive cases N (%) Diagnosis making criteria
Hypertension 77 (82.80) Medical recordsBlood pressure checkup
Diabetes mellitus 23 (24.73)
Medical records
According to OGTT º in cases with
borderline fasting glucose values
Drugs/statins 18 (19.35) Medical records
Drugs/nitrous oxide 12 (12.90) Medical records
Drugs/oral antidiabetic drugs 10 (10.80) Medical records
Cardiovascular diseases
(myocardial infarction, angina pectoris, history
of revascularization, stroke, transitory ischemic
cerebral event, peripheral vascular disease)
24 (25.81)
Medical records followed by clinical examinations
and according to cardiologist and vascular surgeon
report
Gastroduodenal disorders
(gastritis, ulcer)
32 (34.41) Medical records, cases proved by gastro-duodenoscopy
Chronic urinary tract disorders (chronic cystitis
in women, symptoms of prostatism in men) 51 (55.43)
Medical records, clinical criteria, prostat
hypertrophy confirmed by ultrasound
Chronic obstructive pulmonary disease 13 (13.98) Positive spirometry
Allergy (rhinitis, asthma) 9 (9.68) Symptoms, treatment with antiinflammatorydrugs, positive spirometry
Severe osteoarthritis 23 (25.00) Severe symptoms or frequent useof nonsteroid antiinflammatory drugs
Malignancy 14 (15.05) Currently not under active treatment
Osteoporosis 30 (40.00) Medical records, DEXA´
Neuropsychiatric disorders (anxiety/depression,
Parkinson's disease, cognitive impairments) 53 (57.00)
Medical records, use of drugs
with psychotropic action, MMSE*
° OGTT (Oral Glucose Tolerance test)
´ DEXA (Dual-Energy-X-ray-Absorptiometry), the golden standard to diagnose osteoporosis
In 10 cases the data were missing
*Mini Mental State Examination Score (standard screening test on cognitive impairment)
ing nominal, numerical and categorical. One attribute is
chosen as the object of the analysis (target attribute) and
its value is arbitrarily defined, using specific criteria. All
other attributes are used as the input. Patients are ran-
domly grouped, depending on whether they fulfill the
criteria of the target attribute value or not28,30.
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TABLE 2
NUMERICAL DATA USED TO DESCRIBE THE HEALTH STATUS OF SUBJECTS
Parameter Min value measuredin the sample
Max value measured
in the sample Reference range Laboratory test used
Fasting glucose 4.6 13.9 4.4–6.4 mmol/L UV Photometric test with hexokinase
HBA1C 2.89 10.06 4.0–6.4% Immuno – Turbidimetric test
Total cholesterol 3 8.9 <5.0 mmol/L Photometric test with cholesterol-oxidase(CHOD-PAP method)
Triglycerides 0.5 9.3 <1.7 mmol/L
Photometric test with
glycerophosphate-oxidase
(GPO-PAP method)
HDL-cholesterol 0.87 2.53 <1.0 mmol/L for M<1.2 mmol/L for F
Direct method with modified
polyethylenglycol and
a-cyclodextrane-sulphate
Body mass index 20.24 43.1
<20 underweight
20–25 normal weight
26–30 overweight
31–40 obesity
>40 severe obesity
kg/m2
Waist/hip ratio 0.76 1.11
M to 1.0
F to 0.8
with centimetre
Triceps skinfold
thickness 20.24 50.0
(50–65 years)
M 8–23 mm
F 10–35 mm
with caliper
MMSE 14 30 Max »Score« 30 < 24positive on dementia
WBC count 4.06 9.93 3.4–10.0´109/L Electronic blood cell counter
Neutrophils % 28 73.3 44.0–72.0% Light microscopy, Pappenheimer staining
Eosinophils % 0.3 14.3 1.0–7.0% Light microscopy, Pappenheimer staining
Monocytes % 3.6 15.7 2–12% Light microscopy, Pappenheimer staining
Lymphocytes % 18.4 57.7 20–46% Light microscopy, Pappenheimer staining
CRP 0.8 24.5 to 5.0 mg/L Immuno – Turbidimetric test
RBC count 2.63 5.37 4.34–5.72´1012/L Electronic blood cell counter
Hemoglobin 91 167 138–175 g/L Electronic blood cell counter
Serum albumin 33.1 53 35–52 g/L Photometric test with bromocresol-green
Creatinine
clearance 0.72 3.21 1.6–2.94 mL/s/1.73m
2
Estimated from serum creatinine
and 24h urine creatinine
Enzymatic PAP method
Homocysteine 5 25.9 5.0–15.0 mmol/L Radioimmunoassay
Vitamin B12 97.8 885.6 128–648 pmol/L Radioimmunoassay
Folic acid 6.5 43.9 6–39 mmol/L Radioimmunoassay
Cortisol in the
morning 180.3 812.1 154–638 nmol/L Radioimmunoassay
Prolactin in the
morning 14.57 838.18
M 65.7 – 439.8
F 76.3 – 400.7 mIU/L Radioimmunoassay
TSH 0.024 22.7 0.46–4.68 Ul/mL Radioimmunoassay
FT3 4.35 7.96 4.26–8.10 pmol/L Radioimmunoassay
FT4 8.92 18.9 10–28.2 pmol/L Radioimmunoassay
M = males, F = females
Data Mining modelling
All of 93 patients, participating in the study, were di-
vided into two subgroups, depending on whether their
homocysteine levels were above (46 patients) or below
(47 patients) the median value. Using Data Mining meth-
odology for comparing the data, the cluster of parame-
ters, most appropriately associated with hyperhomocy-
steinemia, was extracted from the dataset.
For selected parameters, we repeated the algorithm
application procedure on the dataset (the second-step se-
lection procedure). In this way, we gained better insight
into the clinical context for a particular parameter and
came into how selected parameters are interconnected.
By searching through the databases, interactions be-
tween extracted parameters were meaningfully explai-
ned. Finally, the networked reaction involving hyperho-
mocysteinemia (the clinical model) was created.
Results
The result of the ILLM algorithm application on the
dataset is represented in the form of a pattern consisting
of 6 parameters, expressed with their cut-off values (Ba-
sic model, Table 3). These are parameters indicating: fo-
lic acid and vitamin B12 deficiency (parameters 1 and 2),
chronic renal impairment (parameter 3), normal (not el-
evated) fasting glucose and HbA1c (parameters 4 and 5)
and hyperprolactinemia (parameter 6).
When we analysed the results of the second-step se-
lection procedures, performed separately for each of the
selected parameters, we realised that the results of the
two of these procedures can add value to the information
already obtained by the first-step selection procedure.
These are the results of the ILLM algorithm application
on the parameters indicating vitamin B12 deficiency and
chronic renal impairment (Additional models 1 and 2,
Table 3).
The results of Additional model 1 provide closer in-
sight of the pathogenetic background associated with vi-
tamin B12 deficiency, including also its subclinical form
(starting at the value of 225.50 pmol/L).
Two parameters, extracted in this model, homocy-
steine (>12.05 mol/L) and folic acid (17.00 nmol/L),
overlapping with the data in Basic model, confirm that
correlation does exist between hyperhomocysteinemia
and folic acid and vitamin B12 deficiency.
Other parameters selected in this model provide in-
formation about the clinical conditions associated with
B-vitamin deficiency and hyperhomocysteinemia. These
conditions include: advanced age (>67.5), malnutrition
(indicated by decreased triceps skinfold thickness), chro-
nic gastroduodenal disorders, as well as increased mono-
nuclear leukocyte activity, indicating immune system
dysfunction (parameter »monocyte %>8.35«).
The results of Additional model 2 provide information
about disorders associated with chronic renal impair-
ment – the main clinical condition causing hyperhomo-
cysteinemia. These disorders include: older age (>67.5
years), neuropsychiatric disorders, glucose metabolism
impairment (indicated by fasting glucose values 5.65
mmol/L), inflammation/malnutrition (indicated by se-
rum albumin concentrations 47.15 g/L) and thyroid
gland hormone deficiency (indicated by fT3 concentra-
tions  5.36 pmol/L).
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Fig. 1. »The pattern of disorders« involving hyperhomocysteine-
mia; HPT – the hypothalamus-pituitary-thyroid axis, HPA – the
hypothalamus-pituitary-adrenal axis, PRL – prolactin.
TABLE 3
THE RESULTS OF DATA MINING ANALYSIS
Basic model
»Descriptors of elevated homocysteine levels« (>11.8 mmol/L)
Folic acid  17.75 nmol/L
Vitamin B12 225.50 pmol/L
Creatinine clearance 1.69 mL/s/1.73m2
Fasting glucose 6.25 mmol/L
HbA1c 4.11%
Prolactin >90.24 mIU/L
Additional model 1
»Descriptors of decreased vitamin B12 levels« ( 225.50 pmol/L)
Homocysteine >12.05 mmol/L
Age> 67.5 years
Monocyte % >8.35
Triceps skinfold thickness  31.50 mm
Gastroduodenal disorders = yes
Folic acid  17.00 nmol/L
Additional model 2
»Descriptors of low creatinine clearance« (<1.69 mL/s/1.73m2)
Serum albumin 47.15 g/L
Fasting glucose 5.65 mmol/L
Homocysteine >12.50 mmol/L
Age> 67.5 years
Neuropsychiatric disorders = yes
f T3 5.36 pmol/L
Discussion
Based on a clinical model of hyperhomocysteinemia
(Figure 1), we observed that a large degree of overlap-
ping does exist between the results obtained in this study
and previously existing knowledge. Consequently, the ac-
curacy of the method applied in the study to identify all
relevant factors in a large set of data was confirmed.
In general, the construction of a clinical model may be
important when deciding which parameters should be
collected to investigate a particular clinical feature.
A description of the clinical model – disorders
associated with hyperhomocysteinemia
1. B-vitamin deficiency
Parameters selected in Basic model and Additional
model 1 (Table 3) indicate that correlation does exist be-
tween hyperhomocysteinemia and vitamin B12 and folic
acid deficiency. These results are in accordance with evi-
dence suggesting that B-vitamin deficiency is the main
cause of mild hyperhomocysteinemia13,31.
The exact mechanism, linking these disorders within
the same background, is the metabolic cycle of the amino
acid methionine. This is an essential biochemical reac-
tion, a donor of methyl-groups, necessary for maintain-
ing certain vital biological processes32,33. Folic acid and
vitamin B12 are regulators, while the amino acid ho-
mocysteine is a by-product in this cycle. Hence, B-vita-
min deficiency, even in its subclinical form, can lead to
impairment of this cycle and, subsequently, to hyperho-
mocysteinemia32,33 (Figure 1).
This is connected with the development of disorders
arising from impaired methylation reactions, such as:
DNA damage, genome instability, impaired cell prolifera-
tion and insufficient neurotransmitter synthesis32,33. These
are all intermediate mechanisms during the course of the
development of diseases, such as atherosclerosis, neuro-
degenerative diseases and cancer14,15,33–35. In addition,
hyperhomocysteinemia may independently contribute to
the pathogenesis of these diseases, through mechanisms
such as: increased oxydative stress, impaired lipid me-
tabolism and activation of inflammatory and apoptotic
cell death pathways36,37.
2. Clinical conditions
Based on the results of Additional models, informa-
tion on clinical conditions, causes of B-vitamin deficiency
and hyperhomocysteinemia, are provided. These condi-
tions are: chronic gastroduodenal disorders (implicated
by the results in Additional model 1, Table 3) and chronic
renal impairment (elaborated in Additional model 2, Ta-
ble 3).
2.1. Gastroduodenal disorders
The parameters »gastroduodenal disorders« and »age
>67.5 years« (Additional model 1, Table 3), are likely to
implicate the nutritional reasons for B-vitamin deficien-
cy in elderly subjects (Figure 1). Decreased absorption of
these vitamins, due to chronic gastritis, has long been ac-
cepted as an explanation for the frequent occurrence of
B-vitamin deficiency in older people16,38.
Protein malnutrition, indicated by the parameters
»triceps skinfold thickness 31.5« (Additional model 1,
Table 3) and »serum albumin 47.15« (Additional model
2, Table 3) may be the common mechanism, shared be-
tween chronic gastroduodenal disorders and chronic renal
impairment, associated with B-vitamin deficiency and
hyperhomocysteinemia.
2.2. Chronic renal impairment
In this study, chronic renal impairment, implicated by
the parameter »creatinine clearance 1.69« (Basic model,
Table 3), was recognised as the main clinical condition
leading to hyperhomocysteinemia39–42. Proposed mecha-
nisms include: decreased homocysteine clearance, B-vi-
tamin deficiency, increased oxydative stress and protein
malnutrition39–44. Recently, the unique »malnutrition-in-
flammation-insulin resistance« syndrome has been iden-
tified in a large number of people with chronic renal
impairment45,46.
Our results are likely to implicate the elements of this
syndrome. Thus, the parameter »serum albumin 47.15«
(Additional model 2, Table 3) may be a correlate for mal-
nutrition and inflammation. Parameters »fasting glucose
6.25« and HbA1c 4.11%« (Basic model, Table 3) and
the parameter »fasting glucose 5.65« (Additional model
2, Table 3) may indicate insulin resistance, typically in
patients with chronic renal impairment characterised by
normal (not elevated) fasting blood glucose and gly-
cosylated hemoglobin45,46 (Figure 1).
In addition, this may explain the fact, assumed as con-
troversial in published papers, that homocysteine serum
concentrations do not usually increase in diabetes me-
llitus – a condition characterised by hyperglycemia27.
2.3. Neuroendocrine and neuropsychiatric
disorders
Based on our results, it can be concluded that neuro-
endocrine and neuropsychiatric disorders are also associ-
ated with hyperhomocysteinemia (parameter »prolactin
>90.24«, Basic model, Table 3) and that these disorders
are frequently found in patients with impaired renal
function (parameters »neuropsychiatric disorders=yes«
and »fT35.36«, Additional model 2, Table 3).
Indeed, there is a large body of evidence supporting
these results. For example, multiple endocrine disorders,
including alterations in the hypothalamus-pituitary-ad-
renal axis, the hypothalamus-pituitary-thyroid axis, as
well as in prolactin and thyroid gland hormone metabo-
lism, can be found in persons with chronic renal im-
pairment47,48 (Figure 1).
Thyroid gland hormone hypofunction and hyperho-
mocysteinemia, both disorders frequently occurring in
patients with chronic renal impairment, can be associ-
ated, each of them separately, with mental and cognitive
impairments34,35,49 (Figure 1).
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Hyperprolactinemia may be a result of decreased clea-
rance of the hormone prolactin, due to chronic renal im-
pairment. Alternatively, it may reflect age-related brain
degenerative processes, especially those connected with
changes in the hypothalamus and the pituitary gland –
the central point of the neuroendocrine control50,51. It
has been found that these patients, compared to other
older people, more frequently suffer from anxiety and
mood disorders52. This may, in our results, be indicated
by the parameter »neuropsychiatric disorders« (Addi-
tional model 2, Table 3).
Furthermore, evidence suggests that hyperprolacti-
nemia may contribute to the development of insulin re-
sistance and protein malnutrition53.
Our results could indicate complex relationships ex-
isting between all of these disorders. This is based on the
following parameters: »prolactin«, »low creatinine clear-
ance«, »neuropsychiatric disorders«, »fasting glucose«
and »serum albumin« (Basic model and Additional model
2, Table 3) (Figure 1).
2.4. Chronic autoimmune thyroiditis
There could be another neuroendocrine disorder,
»hidden« in our results. This is hypothyroidism, based on
chronic autoimmune thyroiditis. In this regard, evidence
suggests that this disorder usually appears in co-morbid-
ity with chronic gastritis, both disorders contributing to
hyperhomocysteinemia by different mechanisms17,49,54,55
(Figure 1).
2.5. The immune system impairment
Evidence strongly suggests that chronic activation
and proliferation of immunocomponent cells, during the
course of chronic ageing diseases, such as chronic gastri-
tis and neurodegenerative and vascular diseases, men-
tioned here, may result in increased consumption of B-vi-
tamins, leading to their deficiency and, subsequently, to
hyperhomocysteinemia56–60.
Our results are likely to support this proposed scena-
rio. This is based on the parameter »monocyte %>8.35«,
indicating increased mononuclear leukocyte activity (Ad-
ditional model 1, Table 3) (Figure 1).
3. Hyperhomocysteinemia – a part of the network
reaction
Clearly, by comparing the results with information
gathered from the databases, we could realise, in a step
by step analysis, that all these disorders, involving hy-
perhomocysteinemia, are mutually interconnected, shar-
ing common pathways and operating through a highly
integrated network (Figure 1). This is precisely what the
systems biology theory proposes – functional integration
of the elements of which the system is composed.
A view at the future – a dynamical,
protocol-based and computationally intensive
approach in cardiovascular risk assessment
Functional integration of the elements in the system
is the reason why is it possible to identify almost all rele-
vant risk factors (predictors) of the medical problem un-
der investigation, based on only one single examination
and on a much smaller sample, than by performing large
comparative studies. This is possible by using a systems
biology approach, during which a large number of data,
describing many aspects of the health-status of patients,
are collected and computed. The results must be com-
pared with the existing knowledge.
Moreover, by making minimal corrections to the data,
the same dataset can be used for solving different tasks.
The main aim of this study was the construction of a
clinical model. It may help physicians in patient selec-
tion, based on the clinical criteria. In this way, some hid-
den and previously unrecognised factors or relationships
can be identified.
However, the clinical model may only be the first step
of research protocol used for assessing cardiovascular
risk, or investigation of some other phenomena related to
chronic ageing diseases (Figure 2).
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Fig. 2. Computer-based research protocol.
During the training phase of the protocol, the chal-
lenge will be to repeat the same procedure of parameter
selection on other samples, in order to answer whether
the same factors are extracted when the sample is chan-
ged. This will be valuable information in the process of
predictive mathematical modelling (Figure 2). Namely,
experience gained so far indicate that only multiple para-
meters, jointly, can accurately predict a particular event,
or clinical outcome61. Different types of data are used, in-
cluding socioeconomic and environmental factors, data
from population statistics, clinical and biochemical data,
or information collected from genomics, proteomics, or
other molecular biology fields25,61,62.
Moreover, many mechanisms or variables, not easily
detectable in clinical examinations, can be identified and
included in the estimation of risk.
An important phase of the protocol is the testing of
models on feasibility, by means of their predictive accu-
racy, economical justification and availability of the data
in real-life situations (Figure 2).
Through the ongoing process of application and eval-
uation, models and parameters can further be corrected
(Figure 2).
On-line health data record and computer programme
experts working as a part of medical teams, will be
needed to implement such an approach in clinical pra-
ctice63.
This will be a dynamical, protocol-based and com-
putationally intensive approach in cardiovascular risk
assessment64.
In this way, parameters are selected in a cluster on
the basis of their predictive load, reflecting their »natu-
ral clustering« (functional gathering) within the com-
mon network. Consequently, parameters are adjusted to
specifically describe a particular, specifically defined, group
of patients (Figure 2). This can for example, be a group of
patients with early onset of myocardial infarction (MI),
or a group of older patients with MI, or a group of pa-
tients with MI and (or without) diabetes mellitus, etc.
The realisation of such an approach will be close to the
concept of personalised medicine which has always been
the goal of preventive medicine65.
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POGLED U BUDU]NOST: DINAMI^KI PRISTUP PROCJENE KARDIOVASKULARNOG RIZIKA,
TEMELJEN NA PROTOKU I UPOTREBI KOMPJUTERA
S A @ E T A K
Znanje o kardiovaskularnim ~imbenicima rizika se stalno pove}ava. Shodno tome, postupak procjene kardiovasku-
larnog rizika postaje sve kompliciraniji. Javlja se zahtjev za {to obuhvatnijim, ali i {to vi{e individualiziranim pristu-
pom. Kao na~in postizanja toga cilja, za procjenu kardiovaskularnog rizika predla`emo pristup s aspekta sustavne
biologije. To zna~i potrebu prikupljanja velikog broja podataka, da bi se opisalo zdravstveno stanje pacijenata. Te po-
datke treba obraditi naprednim komjuterskim metodama i usporediti s postoje}im znanjem. Kona~ni cilj toga postupka
je kreiranje klini~kog modela, {to je tek prvi korak cikli~kog protokola koji za krajnji cilj ima procjenu kardiovasku-
larnog rizika. Takvim pristupom bi se mogli identificirati svi potencijalno va`ni ~imbenici rizika na malom uzorku
ispitanika. [tovi{e, zbog »prirodnog« grupiranja podataka, na temelju njihove prediktivne vrijednosti, na taj na~in bi se
mogle specifi~nije definirati rizi~ne skupine pacijenata. Takvu mogu}nost smo testirali na primijeru hiperhomocistei-
nemije, {to je poznati kompleksni ~imbenik pove}anog kardiovaskularnog rizika.
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